CONVINCE trial reveals the effect of long-term colchicine on recurrent stroke and cardiovascular events

FHS
May 16, 2024
5:39 pm

In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis.

TLDR – TDR News highlights – February 2nd to 5th

Get a quick update on today’s essential news with TDR News highlights! We’ve condensed the most important information about Cannabis, Psychedelics, Crypto, and AI into

February 5, 2024

F. Hoffmann-La Roche in cybersecurity: Theme innovation strategy

Share this article F. Hoffmann-La Roche grant share with cybersecurity as a theme is 50% in Q3 2023. Grant share is based on the ratio

January 23, 2024

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

Canadian researchers develop a cell-free DNA-based multimodal assay for early cancer detection in patients with Li-Fraumeni Syndrome, a high-cancer-risk condition. The assay outperforms conventional methods,

October 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.